Aurin Biotech is developing a collection of small molecule complement-inhibiting agents with the potential to become first-in-class therapies for patients with a wide range of conditions.
Our lead drug candidate, AUR1107, is being developed as the world’s first orally available inhibitor of aberrant complement activation. AUR1107 targets complement protein C9 where it effectively blocks formation of the membrane attack complex (MAC). It also targets factor D, which is a key serum protease involved in alternative pathway activation. This makes AUR1107 a promising drug candidate in diseases where pathological activation of the complement cascade is known to occur.
The Phase 1 clinical trial for our initial oral formulation commenced in January 2017. Subsequent clinical trials will aim to demonstrate efficacy in a spectrum of indications.